Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Acquired by Principal Financial Group Inc.

Key Points

• Principal Financial Group boosted its stake in Structure Therapeutics by 63.1% in Q4 and now owns 1,284,210 shares (about 2.12% of the company) valued at roughly $89.3 million.
• Structure Therapeutics reported a quarterly EPS of ($0.49), missing estimates by $0.14 and faces a negative EPS outlook (analysts forecast -1.36 for the year); the stock is volatile with a one‑year range of $15.80–$94.90 and a market cap of $2.89 billion.
• Analyst sentiment is broadly positive on average—MarketBeat shows a "Moderate Buy" consensus and a $109.25 average target price—though ratings are mixed across firms (buys and sells present).

Principal Financial Group Inc. increased its position in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 63.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,284,210 shares of the company's stock after buying an additional 496,726 shares during the period. Principal Financial Group Inc. owned about 2.12% of Structure Therapeutics worth $89,317,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. State of Wyoming purchased a new stake in Structure Therapeutics during the 2nd quarter worth $28,000. EverSource Wealth Advisors LLC grew its holdings in Structure Therapeutics by 530.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company's stock worth $30,000 after acquiring an additional 901 shares in the last quarter. CWM LLC grew its holdings in Structure Therapeutics by 35.2% during the 4th quarter. CWM LLC now owns 480 shares of the company's stock worth $33,000 after acquiring an additional 125 shares in the last quarter. ANTIPODES PARTNERS Ltd grew its holdings in Structure Therapeutics by 39.1% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company's stock worth $114,000 after acquiring an additional 1,146 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Structure Therapeutics during the 2nd quarter worth $129,000. Hedge funds and other institutional investors own 91.78% of the company's stock.

Structure Therapeutics Stock Performance

NASDAQ GPCR opened at $40.84 on Thursday. Structure Therapeutics Inc. Sponsored ADR has a one year low of $15.80 and a one year high of $94.90. The company has a 50-day simple moving average of $52.46 and a 200-day simple moving average of $56.04. The firm has a market capitalization of $2.89 billion, a PE ratio of -51.70 and a beta of -1.31.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.14). Equities analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -1.36 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. BMO Capital Markets set a $145.00 price objective on shares of Structure Therapeutics and gave the stock an "outperform" rating in a report on Tuesday, March 17th. Canaccord Genuity Group assumed coverage on shares of Structure Therapeutics in a report on Monday, April 27th. They set a "buy" rating and a $101.00 price objective for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Structure Therapeutics in a report on Tuesday, April 21st. HC Wainwright decreased their price objective on shares of Structure Therapeutics from $114.00 to $100.00 and set a "buy" rating for the company in a report on Monday, March 16th. Finally, Wall Street Zen raised shares of Structure Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, April 18th. Three analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, Structure Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $109.25.

About Structure Therapeutics

Structure Therapeutics NASDAQ: GPCR is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.